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Original research article
with an estimated 530,000 new cases every year (1). Risk 
factors for HPV infection and development of cervical can-
cer have been identified: early first sexual intercourse, mul-
tiple sexual partners, immune suppression, and tobacco use. 
Other strains of the virus cause less serious health problems 
(2-5).
The prevalence of any type of HPV infection in Italy ranges 
between 7% and 16% among women aged 17-70 years; the 
prevalence of genital HPV infection is higher among sexually 
active Italian women under 25 years of age and amounts to 
24.1% (6, 7).
HPV vaccination is recognized as a valid method of pre-
vention as it is safe and offers long-lasting protection (up to 
8 years). Also, it is particularly effective before first sexual 
intercourse, hence before exposure to the viruses. Trivalent 
and quadrivalent HPV vaccines were introduced in the vac-
cination schedule of 18 European countries by 2010. In Italy, 
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Introduction
Human papillomavirus (HPV) is an important and com-
monly studied virus responsible for sexually transmitted in-
fections (STIs). The high-risk HPV types cause invasive cervical 
cancer, which is the second most common cancer in women 
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vaccination is recommended and offered free of charge to all 
girls at 12 years of age; the vaccine can be administered to 
women from 9 through 45 years of age in 3 doses. By June 
2012, the national coverage for girls born between 1997 and 
1999 was about 70% (8).
In the USA, the Centers for Disease Control and Prevention 
(CDC) and the American Academy of Pediatrics recommend 
HPV vaccination of both girls and boys at ages 11 or 12 years. 
Vaccination is also recommended for females up to 26 years 
and males up to 21 years of age who have not completed the 
vaccine series, and to immunocompromised people aged 
22-26 years (9, 10). HPV vaccination is recommended to 
both genders also in Canada (ages 9-26), Australia, and New 
Zealand (9-26 years for females and 9-15 years for males), but 
not yet in Italy (11, 12).
Vaccinated females will still need regular cervical cancer 
screening (Pap test) beginning at age 21, since vaccination 
protects against most but not all of the HPV types that cause 
cervical cancer. In addition, protective sexual behavior (i.e., 
condom use) is also necessary since the vaccine will not pre-
vent other STIs (9).
The present study was developed considering that HPV 
vaccination campaigns for young women have been carried 
out in all Italian local health units (LHUs). The aim of the anal-
ysis was to evaluate the knowledge, opinions and attitudes 
of Italian mothers – whose daughters had been vaccinated in 
2012 – towards primary (anti-HPV vaccination) and second-
ary (Pap test screening) cervical cancer prevention, as well as 
sources of information and mother-daughter communication 
about health issues.
Methods
The present work is part of a multicenter study called 
PRIN, Programmi di Ricerca di Rilevante Interesse Nazionale 
(Research Projects of National Interest), carried out in 4 cit-
ies (Ferrara, Rome, Cassino and Palermo) by the Sapienza 
 University of Rome, the Catholic University of the Sacred Heart 
of Rome, and the Universities of Palermo, Cassino and Ferrara.
The regions of the participating universities were selected 
for being representative of the different geographical areas 
in Italy relative to knowledge, attitudes and opinions towards 
HPV vaccination, Pap test screening, and reliable sources of 
information about those issues. In particular, Ferrara is in a 
northern region, Rome and Cassino are in central Italy, and 
Palermo is in southern Italy.
The study participants were mothers who accompanied 
their daughters (under-18s and over-18s) to LHUs for HPV vac-
cination and were interviewed in the waiting rooms. Informed 
consent was obtained from the mothers and the study protocol 
was approved by the ethics committee of Sapienza University 
of Rome. The analysis regarding the young women who under-
went vaccination was carried out in 2013 (13, 14).
The questionnaire
The survey was conducted through a questionnaire com-
posed of 3 sections. The first part accounted for 9 questions 
investigating knowledge, opinions, attitudes and sources 
of  information about primary cervical cancer prevention 
 (anti-HPV vaccination) and 3 questions about mother- 
daughter communication. The questionnaire administered 
to mothers of under-18s included 2 additional questions to 
evaluate the mother’s knowledge about HPV vaccination be-
fore receiving the invitation letter from the LHU, and to ascer-
tain who was the first in the family to accept the invitation for 
the vaccination.
The second part was composed of 6 questions relative to 
knowledge, opinions, attitudes and sources of information 
about secondary cervical cancer prevention (Pap test screen-
ing). The third section dealt with sociodemographic data includ-
ing age, nationality, region of residence, religion, educational 
level, and occupational status (6 questions).
Statistical analysis
Data were stored using the database software DB (version 
IV) C. Wayne Ratliff, 1979 and processed with the statistical 
software SPSS 19.0 for Windows (SPSS Inc., Chicago, IL, USA), 
with the level of significance set at p<0.05. Descriptive sta-
tistics were calculated for quantitative variables (mean and 
standard deviation [SD]) and qualitative variables (frequency 
distribution). The first univariate analysis evaluated possible 
differences between mothers of under-18s and over-18s rela-
tive to knowledge, attitudes and opinions about HPV vaccina-
tion, Pap test screening, and other related issues. The second 
univariate analysis evaluated differences between the 2 groups 
of mothers and possible geographical variations regarding the 
sources of information about HPV and Pap test. The chi-square 
test was used in both analyses.
Results
Sociodemographic characteristics
The sample was composed of 444 mothers of young wom-
en who underwent HPV vaccination during the study period. 
The mothers had a mean age of 44.87 years (SD = 5.97) and 
up to 79% resided in central and southern Italian regions. The 
majority of the sample was Italian (97%) and affirmed to be 
catholic (86.4%). The educational level was senior high school 
in 59% of mothers and academic in 35.7%; more than half of 
the mothers worked (65%).
Knowledge, opinions and attitudes towards HPV  
vaccination, Pap test and other sexually related issues
With regard to the questions addressed only to mothers 
of under-18s, it was found that 83.8% knew about HPV vac-
cination before receiving the invitation letter from their LHU 
and 60% were the first to accept the invitation with respect to 
other members of the family. In fact, only 6.8% of daughters 
aged under 18 years were the first to accept it, and 19.4% 
accepted the invitation together with their mothers (data not 
presented in Tab. I).
The sample demonstrated good knowledge about the 
correlation between HPV and cervical cancer (over 85%), 
but was less aware of other diseases caused by HPV viruses 
(Tab. I). More mothers of under-18s knew that a Pap test is 
still  required after HPV vaccination compared with mothers of 
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taBle i - Knowledge, opinions and attitudes of mothers towards HPV vaccination
Variables Mothers of under-18s  
(n = 292)
Mothers of over-18s  
(n = 152)
P value
HPV can cause: N (%; 95% CI) N (%; 95% CI)
 Cervix cancer 261 (89.4;85-92) 132 (86.8; 80.0-91.5) 0.4
 Bladder cancer 14 (4.8;2-7) 4 (2.6; 0.8-6.2) 0.3
 Genital warts 41 (14; 10-18) 25 (16.4; 11.1-22.9) 0.5
 Irritable colon 2 (0.7;0.1-2.2) 4 (2.6; 0.8-6.2) 0.1
 Cancer of the oral cavity 5 (1.7; 0.6-3.7) 7 (4.6; 2.0-8.9) 0.07
 Esophageal cancer 2 (0.7; 0.1-2.2) 2 (1.3; 0.2-4.2) 0.5
 Recurrent cystitis 6 (2.1; 0.8-4) 5 (3.3; 1.2-7.1) 0.4
 Anal cancer 7 (2.4; 1.0-4.6) 4 (2.6; 0.8-6.2) 0.9
 Any other disease 0 (0) 2 (1.3; 0.2-4.2) 0.05
 I don’t know 10 (3.4; 1.7-6) 10 (6.6; 3.3-11.4) 0.1
How should a woman behave towards Pap test after HPV  
vaccination?
 Avoid Pap test because she is vaccinated 3 (1.0; 0.2-2) 1 (0.7; 0.3-1.1) 0.7
 Pap test is still necessary 247 (84.6; 80-88) 113 (74.3; 66.9-80.8) 0.01*
 I don’t know 28 (9.6; 6.5-13.3) 43 (28.3; 21.5-35.8) <0.001*
 Other (seek information from HCW, etc.) 3 (1.0; 0.2-2) 6 (3.9; 1.6-8.0) 0.04*
In regard to sexual activity, when is HPV vaccination required?
 Before first sexual intercourse 174 (59.6; 53.8-65.1) 116 (76.3; 69.0-82.5) <0.001*
 If you think you may have occasional partners 13 (4.5; 2.4-7.3) 5 (3.3; 1.2-7.1) 0.6
 If you have more than 1 partner 9 (3.1; 1.5-5.6) 2 (1.3; 0.2-4.2) 0.3
 If you are 14-17 years old 87 (29.8; 24.7-35.2) 17 (11.2; 6.8-16.9) <0.001*
 After the first sexual intercourse 9 (3.1; 1.5-5.6) 8 (5.3; 2.4-9.7) 0.3
 At any moment 40 (13.7; 10.1-18.0) 21 (13.8; 8.9-20.0) 0.9
 Other 5 (1.8; 1.0-1.8) 3 (2.0; 0.5-5.2) 0.9
At what age should someone undergo HPV vaccination?
 11-13 years 162 (55.5; 49.7-61.1) 87 (57.2; 49.2-64.9) 0.7
 14-17 years 96 (32.9; 27.6-38.4) 47 (30.9; 23.9-38.6) 0.7
 18-21 years 44 (15.1; 11.3-19.5) 21 (13.8; 8.9-20.0) 0.7
 22-26 years 10 (3.4; 1.7-6.0) 10 (6.6; 3.3-11.4) 0.1
 All ages 79 (27.1; 22.2-32.3) 35 (23.0; 16.8-30.2) 0.4
Who should be vaccinated?
 Males 2 (0.7; 0.1-2.2) 0 (0) 0.3
 Females 173 (59.2; 53.5-64.7) 109 (71.7; 64.1-78.4) 0.01*
 Males and females 104 (35.6; 30.2-41.2) 43 (28.3; 21.5-35.8) 0.1
How should the HPV vaccine be provided?
 Free of charge (paid by NHS) 256 (87.7; 83.5-91.0) 121 (79.6; 72.6-85.4) 0.02*
 Fully paid by those who want to be vaccinated 2 (0.7; 0.1- 2.2) 2 (1.3; 0.2-4) 0.5
 Partially paid by vaccinee 22 (7.5; 4.9-11.0) 23 (15.1; 10.0-21.5) 0.01*
 I don’t know 6 (2.1; 0.8-4.2) 6 (3.9; 1.6-8.0) 0.2
You decided to vaccinate your daughter:
 After a deep conversation 45 (16.4; 11.6-19.8) 12 (7.9; 4.3-13.0) 0.01*
 After a superficial conversation 5 (1.8; 1.6-3.7) 0 (0) 0.09
 After discussing with your husband 22 (8.0; 4.9-11.0) 1 (0.7; 0.3-3.2) 0.001*
 After a conflicted discussion 11 (4.0; 1.9-6.4) 20 (13.2; 8.4-19.2) 0.001*
 After consulting a GP/gynecologist 123 (44.9; 36.5-47.8) 33 (21.7;15.6-28.7) <0.001*
 You immediately came to an agreement 70 (25.5; 19.3-29.1) 21 (13.8; 8.9-20.0) 0.005*
 After your daughter’s request for information on HPV 14 (5.1; 2.9-7.7) 11 (7.2; 3.4-12.2) 0.4
HPV = human papillomavirus; CI = confidence interval; HCW = healthcare worker; NHS = National Health Service; GP = general practitioner.
*p<0.05.
Italian mothers’ attitudes towards HPV vaccination and Pap test4 
© 2015 INTM, Italy. Published by Wichtig Publishing
over-18s (84.6% vs. 74.3%; p = 0.01). Some participants did not 
know at all how a woman should behave after undergoing the 
vaccination (28.3% of mothers of over-18s vs. 9.6% of mothers 
of under-18s; p<0.001) and very few mothers (3.9% and 1%, 
respectively; p = 0.04) declared they would seek information 
from a healthcare worker.
HPV vaccination should be administered before the first 
sexual intercourse according to mothers of over-18s (p<0.01), 
and to 14- to 17-year-olds according to mothers of under-18s 
(p<0.01).
More than 50% of the sample stated that the target age 
for HPV vaccination should be 11-13 years. The majority of 
the sample also found that vaccination should include the fe-
male gender only (59.2% of mothers of under-18s and 71.7% 
of mothers of over-18s; p = 0.01). In addition, the vaccine 
should be given free of charge according to 87.7% of mothers 
of under-18s and 79.6% of mothers of over-18s; p = 0.02) or 
be partially charged to the vaccinee (7.5% and 15%, respec-
tively; p = 0.01).
More mothers of under-18s consulted a general practi-
tioner (GP) or gynecologist prior to the decision to vaccinate 
their daughters (p<0.001); came immediately to an agree-
ment (p = 0.005); decided after a deep conversation with 
their daughters (p = 0.01), or after discussing with their hus-
bands (p = 0.001). Conversely, more mothers of over-18s had 
a conflicted discussion with their daughters (p = 0.001).
The knowledge, opinions and attitudes of the partici-
pants toward the Pap test are summarized in Table II. About 
85% of mothers of under-18s and 46% of mothers of over-
18s claimed to know what a Pap test is (p<0.001), and more 
than 85% of the sample had undergone the test themselves. 
More mothers of over-18s had participated in a cervical can-
cer screening program organized by their LHU (p<0.001), but 
declared to be less satisfied with the program than mothers 
of under-18s (p<0.001).
According to our data, mothers of under-18s had a bet-
ter relationship with their daughters: 80.5% affirmed having 
a confidential/intimate relationship (p<0.001), while only 5% 
considered their relationship formal (p<0.001); over 70% talk-
ed about sexually related topics (p<0.001) such as menstrua-
tion (p<0.001), sexually transmitted diseases (p = 0.001), and 
contraception (p = 0.003).
Sources of information
As shown in Table III, mothers of under-18s received infor-
mation on HPV vaccination mainly from their GPs (p = 0.005) 
or gynecologists (p = 0.004), while mothers of over-18s were 
informed through TV (p = 0.001) and books/journals (p = 0.04). 
Geographically, GPs were the main source of information in 
central regions, TV in southern areas, and books/journals in 
northern Italy (p<0.001).
Differences emerged also with regard to the daughters’ 
main source of information, which included their mothers 
(p<0.001), LHUs (p = 0.006) and pediatricians (p = 0.02) for girls 
under 18. Geographically, daughters were mostly informed by 
their mothers (p<0.001), GPs (p = 0.04), and gynecologists 
(p = 0.03) in central Italy. Important sources particularly in 
southern regions were friends (p<0.001), TV (p = 0.005), and 
websites (p = 0.01).
Over 80% of the mothers of the sample declared they 
were satisfied with the information received from their gy-
necologist during the Pap test, mostly in central Italy (89%). 
Nevertheless, they did not receive specific information about 
HPV infections during the medical visit (52% of mothers of 
under-18s and 62% of mothers of over-18s), especially those 
residing in northern regions.
Discussion
According to the most recent available data, the cervi-
cal cancer incidence and mortality among Italian women in 
2005 were 1.6% and 0.6%, respectively (15). Preventive mea-
sures against cervical cancer are essentially 2: cervical cancer 
screening with the Pap test and anti-HPV vaccination (16).
In agreement with our research, most studies (17-19) re-
port high rates of parental acceptance of HPV vaccination: 
we found 60% of acceptance toward vaccine administration 
among mothers. Our sample demonstrated good knowledge 
about the relation between HPV and cancer, which was not 
observed in the study by Barnack et al (19).
Numerous variables may influence the decision of par-
ents to vaccinate their children. Parental consent is gen-
erally required for medical interventions to adolescents 
younger than 18 years, so parents’ perceptions about sexu-
ality, vaccination and STIs may play an important role in de-
termining the uptake of the HPV vaccine among adolescent 
girls (20).
Physicians have an important role in cancer prevention 
and thus in providing evidence-based recommendations to 
parents, especially the hesitant ones (21). Family physicians 
are the principal source of information for most mothers (22), 
and well-informed mothers are more prone to having their 
daughters vaccinated (23). We found that the majority of 
mothers decided to vaccinate their daughters after consult-
ing a general practitioner or gynecologist.
Regarding the age at which girls should be vaccinated, the 
majority of respondents in a study considered young age to 
be appropriate for HPV vaccination, in particular before first 
sexual intercourse (24). Consistent with these findings, we 
found that about 60% of mothers of under-18s and 76% of 
mothers of over-18s believed vaccination should be done be-
fore sexual activity.
Most mothers identified the ages from 11 to 13 as op-
timal for HPV vaccination. This is in contrast with the study 
by Jaccard et al (25), where mothers preferred vaccinat-
ing their daughters at a later age, probably because some 
parents are convinced that HPV vaccination leads to sexual 
disinhibition.
At the age of 13.4 and 11.8 years, respectively, 2.0% and 
0.5% of women have had their first sexual experience; about 
50% of women contract genital HPV infections within the first 
2 years of sexual activity (26). Family physicians and public 
health professionals should address these issues by underlin-
ing that the highest rate of protection is obtained when the 
vaccine is administered before the first sexual experience. 
Hence, vaccinating 10- to 12-year-olds can protect the major-
ity of girls. Several studies have demonstrated the importance 
of practitioner recommendation in HPV vaccine uptake for ad-
olescents as well as in health promotion interventions (24, 27).
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TABLE II - Knowledge, opinions and attitudes of mothers towards Pap test and other sexually related issues
Variables Mothers of under-18s  
(n = 292)
Mothers of over-18s  
(n = 152)
P value
Do you know what is a Pap test? N (%; 95% CI) N (%; 95% CI)
 Yes 249 (85.3; 80.7-88.9) 70 (46.1; 38.3-54.0) <0.001*
 No 43 (14.7; 11.1-19.2) 82 (53.9; 46.0-61.7)
Have you ever had a Pap test?
 Yes 252 (86.3; 81.9-89.8) 138 (90.8; 85.1-94.4) 0.2
 No 40 (13.7; 10.2-18.1) 14 (9.2; 5.6-14.9)
Have you ever participated in any cervical cancer screening 
program organized by your LHU?
 Yes 65 (24.2; 19.4-29.6) 35 (48.6; 37.4-59.9) <0.001*
 No 204 (75.8; 70.4-80.6) 37 (51.4; 40.1-62.6)
If you answered yes to the previous question, were you satisfied 
with the screening program?
 Very much/much 64 (55.2; 46.1-63.9) 27 (49.1; 36.4-61.9)
 Sufficiently 24 (20.7; 14.3-28.9) 23 (41.8; 29.7-55.0) <0.001*
 Barely 25 (21.6; 15.0-29.9) 4 (7.3; 2.9-17.2)
 Not at all 3 (2.6; 0.9-7.0) 1 (1.8; 0.3-9.6)
How do you consider your relationship with your daughter?
 Confidential/intimate 235 (80.5; 75.5-84.6) 58 (38.2; 30.8-46.1) <0.001*
 Formal 15 (5.1; 3.1-8.3) 43 (28.3; 21.7-35.9) <0.001*
 Conflictual 25 (8.6; 5.9-12.3) 8 (5.3; 2.7-10.0) 0.2
 Authoritative 7 (2.4; 1.2-4.9) 6 (3.9; 1.8-8.3) 0.4
 Other (i.e., normal, borderline normal, etc.) 13 (4.5; 2.6-7.5) 2 (1.3; 0.3-4.6) 0.08
Do you talk about sexually related topics with your daughter?
 Yes 212 (76.8; 71.5-81.4) 64 (56.1; 47.0-64.9)
 No 33 (12.0; 8.6-16.3) 26 (22.8; 16.1-31.3) <0.001*
 No, but I would love to 31 (11.12; 8.0-15.5) 24 (21.1; 14.6-29.4)
If you answered yes to the previous question, what do you talk 
about?
 Menstruation 185 (71.2; 65.4-76.3) 46 (30.3; 23.5-38.0) <0.001*
 STDs 97 (37.3; 31.7-43.3) 33 (21.7; 15.9-28.9) 0.001*
 Contraception 81 (31.2; 25.8-37.0) 42 (27.6; 21.1-35.2) 0.5
 Sexuality 75 (28.8; 23.7-34.6) 24 (15.8; 10.8-22.4) 0.003*
 Other 5 (1.9; 0.8-4.4) 0 (0; 0.0-2.5) 0.09
CI = confidence interval; LHU = local health unit; STD = sexually transmitted disease.
*p<0.05.
In our sample, most mothers (85%) were aware of the 
Pap test and had it done themselves. This practice may have 
encouraged them to accept screening for their daughters as 
well; in fact, a study reported that women who participat-
ed in cervical cancer screening programs were more prone 
to vaccinating their daughters than women who had never 
had a Pap test (28). Our findings confirm the evidence for 
the key role of parents in orienting the decision to vaccinate 
their daughters and strengthen the necessity of vaccination 
 programs to tackle parents beliefs about sexual disinhibition 
and promote the importance of vaccination (29).
In the US, the aim of Healthy People 2020 is to achieve 
high population vaccination coverage, but unfortunately only 
part of the population is willing to consider HPV vaccination 
(30). In this sense, the source of information can play a crucial 
role. Our results showed that over 80% of mothers were sat-
isfied with the information received from their gynecologist 
during the Pap test; the satisfaction rate was highest among 
mothers from central Italy (89%). Furthermore, we found that 
websites were an important source of information, especially 
in the south of Italy. These findings are consistent with other 
studies (14, 31) showing that the media play a key role in 
Italian mothers’ attitudes towards HPV vaccination and Pap test6 
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health matters; in fact, about 47% of Europeans seek health 
information online.
The major strength of this study is that it provides infor-
mation on HPV prevention among mothers of young Italian 
women. These data may be considered as nationally repre-
sentative because the study analyzed women from northern, 
central and southern Italy.
However, our study has some limitations. We analyzed 
a sample of mothers attending health facilities with their 
daughters, and the results may have been different in other 
populations or settings, although we performed a multicenter 
study. Mothers who participate in these type of studies could 
be more favorable toward vaccination than those who refuse 
to participate or those who do not accompany their daughters 
when seeing a physician (32). Also, due to the cross- sectional 
design it is difficult to establish whether the knowledge about 
the HPV vaccine was related to information given during the 
vaccination and whether it influenced the decision to under-
go vaccination (33).
In our sample, the majority of mothers were in favor of 
HPV vaccination at an early age. This is important even if the 
sample might not have been representative of the whole Ital-
ian population. The present study provides useful information 
for the development of effective public health interventions 
that may improve parental acceptance of HPV vaccination 
and therefore vaccination coverage in adolescents.
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